Expected Moves

Actual outcome: Bear · $0.46 at outcome

ACTU experienced a sharp decline due to a significant earnings miss and downward guidance, which exceeded market expectations. The company reported lower-than-expected revenue and profit, with management citing weaker-than-anticipated demand in key markets. This led to a re-rating of the stock, particularly in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -20.9% from 2026-10-06 to 2026-10-07 (~2.6σ vs typical 1d vol). Target evaluation date 2026-10-08 (not yet reached as of 2026-10-07). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-10-08: -20.9% from 2026-10-06 (~2.6σ). Target date 2026-10-08 reached; move through 2026-10-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-10-13: -26.7% from 2026-10-12 (~3.1σ). Target date 2026-10-08 reached; move through 2026-10-13 observed.

Actual outcome: Mixed · $1.06 at outcome

ACTU reported Q2 earnings in line with expectations, with an EPS actual of -0.2 versus an estimate of -0.2. The stock rallied 5.0% following the event due to critical mid-stage clinical updates for elraglusib, which signaled progress in the drug's development. The positive clinical data and forward guidance on potential regulatory milestones drove investor confidence, despite the earnings miss.

Actual outcome: Bear · $1.40 at outcome

Actuate Therapeutics executed a strategic equity financing to address its precarious cash runway. While the offering provided necessary capital to sustain operations, the resulting equity dilution weighed heavily on shares, driving a 16.3% decline as investors priced in the expanded share count.

Actual outcome: Bull · $2.51 at outcome

The anticipated dilutive equity financing did not materialize during the event window. Instead, the market focused on the recent FDA clearance of the company's IND application for oral elraglusib, a positive regulatory milestone that allowed the stock to hold steady near the $2.50 bull target without the expected downward pressure from a capital raise.

Actual outcome: Bear · $2.50 at outcome

Actuate Therapeutics reported in-line Q4 EPS of -$0.20, but the stock failed to gain traction and fell well below the $3.50 bear floor. Despite announcing a new strategic research initiative to combine Elraglusib with RAS inhibitors just prior to the report, the lack of a meaningful positive catalyst or reassuring financial runway update left investors cautious, driving the stock lower.